omarigliptin

Omarigliptin is a long-acting, selective dipeptidyl peptidase 4 (DPP-4) inhibitor developed as an oral antidiabetic agent for the treatment of type 2 diabetes mellitus. It is notable for its once-weekly dosing regimen, distinguishing it from other DPP-4 inhibitors that are typically administered daily. Omarigliptin works by inhibiting the DPP-4 enzyme, thereby increasing levels of incretin hormones such as GLP‑1 and GIP, which in turn enhance glucose-dependent insulin secretion and suppress glucagon release. This mechanism leads to improved glycemic control with a low risk of hypoglycemia. The drug was first approved in Japan under the brand name Marizev and has undergone clinical trials globally for type 2 diabetes mellitus and chronic renal insufficiency[5][9][3].

Brand names

Marizev

Other names

Omarigliptina1226781-44-7CVP59Q4JE1CVP-59Q4JE1CVP 59Q4JE1